Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial -

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Information type: Other primary research
Source: The Lancet Oncology
Specialities: Cancers
Summary
In this Phase II study (n=117), the PD-1 immune checkpoint inhibitor antibody nivolumab (3 mg/kg IV every 2 weeks) was associated with an objective response rate of 14.5% (95% CI 8.7-22.2%) in patients with advanced, refractory, squamous non-small-cell lung cancer.
UKMi comment
The US FDA has agreed to review nivolumab as a treatment for advanced squamous non-small cell lung cancer after prior therapy; the submission is based on data from this Phase II trial.
Related links: PharmaTimes report on US application for approval